SCHEMBL160453

SCHEMBL160453

Fc1[c]cccc1OC(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MPL P40238 1/20 0.34
KCNN4 O15554 1/20 0.33
SCN9A Q15858 2/20 0.33
PDE2A O00408 1/20 0.33
GAA P10253 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
HSD11B1 P28845 2/20 0.31
ALDH1A1 P00352 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TRPA1 O75762 1/20 0.30
HTR2A P28223 1/20 0.30
HTR2C P28335 1/20 0.30
HTR2B P41595 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16953093 0.82 KCNH2 (0.33)
SCHEMBL622920 0.79 DDB1 (0.34) EPHX2KDM4EMPLSCN9AGAA
SCHEMBL1069544 0.78 HSD11B1 (0.36) EPHX2KDM4EMPLSCN9APDE2A
SCHEMBL457854 0.78 SCN9A (0.32) EPHX2KDM4EMPLSCN9AGAA
SCHEMBL5126421 0.78 MPL (0.36) EPHX2KDM4EMPLSCN9APDE2A
SCHEMBL591521 0.78 GRIA1 (0.36) EPHX2KDM4ESCN9AGAARXRA
SCHEMBL1046580 0.78 KDM4E (0.34) EPHX2KDM4EMPLSCN9AGAA
SCHEMBL7683503 0.76 MRGPRX1 (0.33) EPHX2MPLSCN9AHSD11B1TRPA1
SCHEMBL1567636 0.75 EPHX2 (0.35) EPHX2MPLPDE2A
SCHEMBL5535846 0.75 MPL (0.35) KDM4EMPLSCN9ATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649229-B2 Amide compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-05-16 US claimed
US-11649223-B2 Amino compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-05-16 US claimed
CN-110536892-B Novel bicyclic pyrazole derivatives 拜耳动物保健有限责任公司 2023-05-12 CN claimed
CN-114907361-A Trimeric heterocyclic derivative and application thereof 北京八亿时空液晶科技股份有限公司 2022-08-16 CN claimed
US-11130768-B2 Bicyclic pyrazole derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-09-28 US claimed
CN-113164459-A Monoacylglycerol lipase modulators 詹森药业有限公司 2021-07-23 CN claimed
US-20210122733-A1 AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. 2021-04-29 US claimed
US-20210115034-A1 AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. 2021-04-22 US claimed
US-10919884-B2 Amide compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2021-02-16 US claimed
US-10906887-B2 Amino compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2021-02-02 US claimed
CN-105209464-B P2X7 modulators 詹森药业有限公司 2019-01-01 CN claimed
US-9890167-B2 Pyrazine compounds for the treatment of infectious diseases HOFFMANN-LA ROCHE INC. (US) 2018-02-13 US claimed
US-20170368039-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA TM, LLC (US) 2017-12-28 US claimed
EP-3245206-A1 PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES F. Hoffmann-La Roche AG (CH) 2017-11-22 EP claimed
US-20160237090-A1 NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES HOFFMANN-LA ROCHE INC. (US) 2016-08-18 US claimed
WO-2016113273-A1 PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2016-07-21 WO claimed
US-20140294805-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO EARLY DISCOVERY, INC. 2014-10-02 US claimed
EP-2611804-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Forma TM, LLC. (US) 2013-07-10 EP claimed
WO-2012031197-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA THERAPEUTICS, INC. (US) 2012-03-08 WO claimed
US-7226926-B2 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors MERCK SHARP & DOHME LTD. (GB) 2007-06-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122733-A1 AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS CFD, TFPI, CFH EPHX2 2718/4885KDM4E 3191/4885MPL 403/4885
US-10919884-B2 Amide compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH EPHX2 1348/4885KDM4E 2775/4885MPL 793/4885
US-11649229-B2 Amide compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH EPHX2 1348/4885KDM4E 2775/4885MPL 793/4885
US-20160237090-A1 NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES HAVCR2, NR1H4, ZC3HAV1 EPHX2 2498/4885KDM4E 4051/4885MPL 349/4885
US-20170368039-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 EPHX2 3205/4885KDM4E 2133/4885MPL 4294/4885
US-20140294805-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 EPHX2 3205/4885KDM4E 2133/4885MPL 4294/4885
US-11649223-B2 Amino compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH EPHX2 2718/4885KDM4E 3191/4885MPL 403/4885
US-10906887-B2 Amino compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH EPHX2 2718/4885KDM4E 3191/4885MPL 403/4885
US-11130768-B2 Bicyclic pyrazole derivatives CYP1B1, CYP3A43, CYP3A5 EPHX2 322/4885KDM4E 3843/4885MPL 1399/4885
US-20210115034-A1 AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS CFD, TFPI, CFH EPHX2 1348/4885KDM4E 2775/4885MPL 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.